HEM

Hemostemix Inc. (HEM)

Market Closed
12 Dec, 20:00
TSX-V TSX-V
TSX-V TSX-V Primary
XFRA XFRA
CA$
0. 10
0
0%
CA$
- Market Cap
- P/E Ratio
0% Div Yield
256,766 Volume
0 Eps
CA$ 0.1
Previous Close
Day Range
0.09 0.1
Year Range
0.07 0.42
Want to track HEM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

HEM closed yesterday higher at CA$0.1, an increase of 0% from Thursday's close, completing a monthly increase of 11.76% or CA$0.01. Over the past 12 months, HEM stock lost -20.83%.
HEM is not paying dividends to its shareholders.
The last earnings report, released on Dec 01, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Hemostemix Inc. has completed 1 stock splits, with the recent split occurring on Dec 30, 2020.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).

HEM Chart

No Data

Hemostemix Inc. (HEM) FAQ

What is the stock price today?

The current price is CA$0.10.

On which exchange is it traded?

Hemostemix Inc. is listed on TSX-V.

What is its stock symbol?

The ticker symbol is HEM.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has Hemostemix Inc. ever had a stock split?

Hemostemix Inc. had 1 splits and the recent split was on Dec 30, 2020.

Hemostemix Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Thomas A. Smeenk B.A., BA Hons CEO
TSX-V Exchange
CA4236943060 ISIN
Canada Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Hemostemix Inc. is a Calgary-based clinical stage biotechnology company committed to the development, manufacturing, and commercialization of innovative blood-derived stem cell therapies for a variety of medical conditions. Utilizing a patient's own blood as a non-invasive source of therapeutic cells, Hemostemix focuses on pioneering treatments that are both effective and devoid of the complexities associated with traditional stem cell therapies. The company's operations span across Canada and the United States, where it is dedicated to pushing the boundaries of regenerative medicine through its cutting-edge research and clinical trials.

Products and Services

  • ACP-01 for Vascular Diseases

    • An autologous cell therapy product currently in Phase II clinical trials aimed at treating a wide range of vascular diseases including cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. ACP-01 leverages the healing capabilities of stem cells derived from the patient's own blood, promoting a non-invasive and personalized approach to treatment.

  • Synergetic Cell Populations

    • Hemostemix is developing therapeutic products consisting of synergetic cell populations designed to enhance the regenerative capabilities of the body. These cell populations are cultivated to work in harmony, targeting specific ailments and accelerating the body's natural healing processes.

  • Neural Cell Precursors

    • The company is working on deriving neural cell precursors from blood cells. These precursors have the potential to treat neurological conditions by repairing or replacing damaged neurons, thus offering hope for diseases currently considered untreatable.

  • Cardiomyocyte Cell Precursors

    • Cardiomyocyte cell precursors are being developed to aid in the regeneration of heart tissue. This innovative approach could revolutionize the treatment of heart diseases by using the patient's own blood-derived cells to foster natural healing and repair of damaged heart muscle.

Contact Information

Address: 707-7th Avenue SW
Phone: 905-580-4170
Affiliate Program About Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark